MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term

J. Haartsen; T. Spelman; J. Baker; S. Agland; J. Lechner-Scott; T. Burke; S. Vucic; L. Rath; O. Skibina; M. Toubia; M. Slee; S. McGregor; B. Taylor; A. O'Connell; M. Barnett; S. Baker; M. Sharma; S. Hodgkinson; S. Walters; A. Kermode; W. Hayes; E. Butler; N. Shuey; C. Shaw; R. Portley; T. Hardy; I. L. Tan; H. Butzkueven

MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term

J. Haartsen, T. Spelman, J. Baker, S. Agland, J. Lechner-Scott, T. Burke, S. Vucic, L. Rath, O. Skibina, M. Toubia, M. Slee, S. McGregor, B. Taylor, A. O'Connell, M. Barnett, S. Baker, M. Sharma, S. Hodgkinson, S. Walters, A. KermodeW. Hayes, E. Butler, N. Shuey, C. Shaw, R. Portley, T. Hardy, I. L. Tan, H. Butzkueven

Centre for Neuromuscular and Neurological Disorders (Perron Institute)

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	342-343
Journal	Multiple Sclerosis Journal
Volume	22
Publication status	Published - 2016

Cite this

Haartsen, J., Spelman, T., Baker, J., Agland, S., Lechner-Scott, J., Burke, T., Vucic, S., Rath, L., Skibina, O., Toubia, M., Slee, M., McGregor, S., Taylor, B., O'Connell, A., Barnett, M., Baker, S., Sharma, M., Hodgkinson, S., Walters, S., ... Butzkueven, H. (2016). MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term. Multiple Sclerosis Journal, 22, 342-343.

@article{1721c80e308a494c8f243b240590eb62,

title = "MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term",

author = "J. Haartsen and T. Spelman and J. Baker and S. Agland and J. Lechner-Scott and T. Burke and S. Vucic and L. Rath and O. Skibina and M. Toubia and M. Slee and S. McGregor and B. Taylor and A. O'Connell and M. Barnett and S. Baker and M. Sharma and S. Hodgkinson and S. Walters and A. Kermode and W. Hayes and E. Butler and N. Shuey and C. Shaw and R. Portley and T. Hardy and Tan, {I. L.} and H. Butzkueven",

year = "2016",

language = "English",

volume = "22",

pages = "342--343",

journal = "Multiple Sclerosis Journal",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

}

Haartsen, J, Spelman, T, Baker, J, Agland, S, Lechner-Scott, J, Burke, T, Vucic, S, Rath, L, Skibina, O, Toubia, M, Slee, M, McGregor, S, Taylor, B, O'Connell, A, Barnett, M, Baker, S, Sharma, M, Hodgkinson, S, Walters, S, Kermode, A, Hayes, W, Butler, E, Shuey, N, Shaw, C, Portley, R, Hardy, T, Tan, IL & Butzkueven, H 2016, 'MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term', Multiple Sclerosis Journal, vol. 22, pp. 342-343.

MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term. / Haartsen, J.; Spelman, T.; Baker, J. et al.
In: Multiple Sclerosis Journal, Vol. 22, 2016, p. 342-343.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term

AU - Haartsen, J.

AU - Spelman, T.

AU - Baker, J.

AU - Agland, S.

AU - Lechner-Scott, J.

AU - Burke, T.

AU - Vucic, S.

AU - Rath, L.

AU - Skibina, O.

AU - Toubia, M.

AU - Slee, M.

AU - McGregor, S.

AU - Taylor, B.

AU - O'Connell, A.

AU - Barnett, M.

AU - Baker, S.

AU - Sharma, M.

AU - Hodgkinson, S.

AU - Walters, S.

AU - Kermode, A.

AU - Hayes, W.

AU - Butler, E.

AU - Shuey, N.

AU - Shaw, C.

AU - Portley, R.

AU - Hardy, T.

AU - Tan, I. L.

AU - Butzkueven, H.

PY - 2016

Y1 - 2016

UR - https://publons.com/publon/4889941/

M3 - Abstract/Meeting Abstract

SN - 1352-4585

VL - 22

SP - 342

EP - 343

JO - Multiple Sclerosis Journal

JF - Multiple Sclerosis Journal

ER -

MSFIRST - utilising a longitudinal, prospective, comparative drug safety module for use in everyday MS clinical practice to evaluate and track incidence and characteristics of safety outcomes in MS patients on therapy over the long term

Other files and links

Cite this